Lefid

Leflunomide, the active ingredient in Lefid, is an immunomodulatory DMARD presented as an oral dosage form for oral use. It is employed to treat rheumatoid arthritis and psoriatic arthritis in adult patients, helping to reduce joint inflammation and slow disease progression.

GNH USA supplies Lefid as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable global distribution, ensuring timely delivery and regulatory compliance across multiple markets.

Lefid (leflunomide) is used in the management of inflammatory joint diseases that involve autoimmune mechanisms.

- Rheumatoid arthritis: reduces joint inflammation, pain, and slows structural damage in adult patients. - Psoriatic arthritis: alleviates skin and joint symptoms, improving functional ability. - Active disease in adults: helps control disease activity when conventional therapies are insufficient.

Lefid may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Diarrhea: loose stools or increased frequency. - Nausea: feeling of queasiness or upset stomach. - Alopecia: thinning or loss of hair. - Rash: skin irritation or redness. - Headache: mild to moderate head pain. - Hypertension: elevated blood pressure readings.

Serious or Rare Side Effects: - Hepatotoxicity: significant liver enzyme elevation or liver injury. - Severe infections: opportunistic or bacterial infections requiring medical attention. - Stevens‑Johnson syndrome: severe skin reaction with blistering. - Pulmonary toxicity: interstitial lung disease or severe breathing difficulties. - Bone marrow suppression: anemia, leukopenia, or thrombocytopenia. - Severe hypertension: markedly high blood pressure that may lead to complications.

When prescribing Lefid, clinicians should consider several safety measures to minimize risk.

- Pregnancy: contraindicated; teratogenic risk, avoid use in pregnant women. - Liver function: monitor hepatic enzymes before initiation and periodically during therapy. - Blood pressure: regularly assess for hypertension, especially in patients with cardiovascular risk factors. - Infections: evaluate for active infections; defer treatment until resolved. - Live vaccines: do not administer live vaccines during treatment. - Store below 25°C: keep in the original packaging, protect from moisture and light.

Lefid can interact with several medicines, altering efficacy or safety.

Major Interactions (Avoid): - Warfarin: increased anticoagulant effect may lead to bleeding. - CYP1A2 inhibitors (e.g., fluvoxamine): raise leflunomide plasma levels, increasing toxicity risk.

Moderate Interactions (Monitor Closely): - Methotrexate: additive hepatotoxicity; monitor liver function tests. - Live vaccines: reduced efficacy; avoid concurrent administration. - Other immunosuppressants: heightened infection risk; close clinical monitoring required.